2025 Mar 10. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–.
PMID:25905351
Drug-Induced Atypical Lipodystrophy.
Rajakumar P, Mahadevan S, Asirvatham AR, Ranjan A.
2018 Mar 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.
Mifepristone induced liver injury in a patient with Cushing syndrome: a case report and review of the literature.
Ault TA, Braxton DR, Watson RA, Marcus AO, Fong TL.
J Med Case Rep. 2023 Feb 3;17(1):33. doi: 10.1186/s13256-022-03696-x.
PMID:36732814
[Secondary diabetes].
Nomiyama T, Yanase T.
Nihon Rinsho. 2015 Dec;73(12):2008-12.
PMID:26666145
Drug-induced deaths - United States, 1999-2010.
Mack KA; Centers for Disease Control and Prevention (CDC).
MMWR Suppl. 2013 Nov 22;62(3):161-3.
PMID:24264508
Antiprogesterones.
Norman J.
Br J Hosp Med. 1991 Jun;45(6):372-5.
PMID:2070168
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, Mariash CN, Terzolo M, Ellison N, Moraitis AG.
Front Endocrinol (Lausanne). 2021 Jul 14;12:662865. doi: 10.3389/fendo.2021.662865. eCollection 2021.